Table 3.
Top 25 Drugs by Expenditures Overall in 2020
| Druga | 2020 Expenditures ($ Thousands) |
Percent Change From 2019 |
|---|---|---|
| Adalimumab | 24,856,877 | 11.5 |
| Apixaban | 12,805,307 | 29.9 |
| Insulin glargine | 9,702,808 | 2.1 |
| Dulaglutide | 8,692,911 | 34.1 |
| Ustekinumab | 8,320,398 | 25.3 |
| Pembrolizumab | 8,295,581 | 26.6 |
| Bictegravir/emtricitabine/tenofovir alafenamide | 8,006,918 | 56.3 |
| Etanercept | 7,768,483 | –3.5 |
| Rivaroxaban | 6,628,084 | 10.2 |
| Sitagliptin | 6,247,191 | 3.5 |
| Insulin aspart | 5,914,825 | –2.0 |
| Empagliflozin | 5,688,217 | 46.8 |
| Semaglutide | 5,631,358 | 132.0 |
| Insulin lispro | 5,548,970 | –4.0 |
| Immune globulin | 4,996,557 | 6.1 |
| Liraglutide | 4,714,827 | –5.7 |
| Secukinumab | 4,440,378 | 18.6 |
| Infliximab | 4,180,420 | –16.9 |
| Budesonide/formoterol | 4,145,219 | 6.7 |
| Inactivated influenza virus | 3,993,728 | 23.6 |
| Nivolumab | 3,945,153 | –9.9 |
| Rituximab | 3,900,350 | –12.1 |
| Ibrutinib | 3,855,095 | 10.3 |
| Epinephrine | 3,848,533 | –1.4 |
| Palbociclib | 3,784,139 | 6.4 |
aFor each drug listed, the expenditures shown are the total for branded and generic products (including biosimilars) and of various dosage forms.